Stocklytics Platform
Asset logo for symbol RVNC
Revance Therapeutics
RVNC49
$5.13arrow_drop_down2.37%-$0.12
Asset logo for symbol RVNC
RVNC49

$5.13

arrow_drop_down2.37%

Income Statement (RVNC)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$34.57M-$46.06M-$53.10M-$41.86M-$64.34M
EBITDA-$33.14M-$44.08M-$51.68M-$39.74M-$60.81M
gross Profit$46.32M$35.04M$50.90M$37.36M$36.82M
NET Income-$37.47M-$53.15M-$55.69M-$141.17M-$67.31M
total Revenue$65.38M$51.93M$69.79M$56.77M$58.13M

Balance Sheet (RVNC)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt$409.90M$342.61M$340.55M$308.58M$291.15M
stockholders Equity-$129.73M-$98.67M-$151.60M-$106.20M$26.78M
total Assets$494.79M$508.11M$478.45M$532.48M$597.53M
total Debt$491.63M$475.77M$478.43M$487.89M$432.38M
total Liabilities$624.53M$606.79M$630.05M$638.68M$570.74M

Cash Flow (RVNC)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow-$3.41M$92.82M-$1.62M$37.46M$97.47M
free Cash Flow-$41.59M-$67.65M-$44.51M-$55.46M-$53.11M
investing Cash Flow-----$39.53M
operating Cash Flow-$41.12M-$65.93M-$42.73M-$50.96M-$53.38M

Revance Therapeutics (RVNC) Financials

Revance Therapeutics Inc (RVNC) is a biotechnology company that specializes in the development and commercialization of novel aesthetic and therapeutic products. The company's financial performance is reflected in its income statement, which details its revenue, expenses, and net income from stockholders. In the latest reported period, Revance Therapeutics Inc generated total revenue of $22.5 million, representing a significant increase compared to the previous year. The company's gross profit was $14.3 million, indicating a healthy margin on its products and services. However, after accounting for operating expenses, the company reported an EBIT loss of $78.9 million.
Revance Therapeutics Inc's balance sheet shows a strong financial position with total assets of $604.8 million. The company has a significant amount of cash equivalents, which provide liquidity and flexibility in its operations. Additionally, Revance Therapeutics Inc has a favorable stockholders equity of $285.6 million, indicating a solid base of shareholder support. However, the company also has total debt of $223.4 million, which should be carefully managed to avoid excessive leverage.
In terms of cash flow, Revance Therapeutics Inc has been focused on financing its operations and investing in research and development initiatives. The company has a positive operating cash flow, indicating that its core business is generating cash. However, the company has been utilizing its financing cash flow to meet its capital requirements and fund its growth strategies. The investing cash flow reflects the company's investments in property, plant, and equipment, as well as acquisitions of intangible assets. Overall, Revance Therapeutics Inc strives to maintain a balanced cash flow to support its long-term growth and profitability.
add Revance Therapeutics  to watchlist

Keep an eye on Revance Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media